Apple Inc
AAPL
$142.99
(-0.9%)
Alphabet Inc - Class C
GOOG
$99.01
(-0.86%)
Alphabet Inc - Class A
GOOGL
$97.97
(-0.88%)
Amazon.com Inc.
AMZN
$101.95
(-1.17%)
Microsoft Corporation
MSFT
$246.97
(-0.34%)
Meta Platforms Inc - Class A
FB
$196.64
(+0.51%)
Berkshire Hathaway Inc. - Class B
BRK.B
$310.25
(-0.41%)
Alibaba Group Holding Ltd - ADR
BABA
$111.08
(+0.8%)
JPMorgan Chase & Co.
JPM
$140.24
(+0.2%)
Johnson & Johnson
JNJ
$164.26
(+0.51%)
Bank Of America Corp.
BAC
$35.91
(+1.2%)
Exxon Mobil Corp.
XOM
$115.43
(-0.5%)
Wells Fargo & Co.
WFC
$47.26
(+0.82%)
Visa Inc - Class A
V
$228.74
(-0.64%)
Walmart Inc
WMT
$143.81
(-0.04%)
Shell Plc - ADR
RDS.B
$51.06
(0%)
Shell Plc - ADR (Representing Ordinary Shares - Class A)
RDS.A
$51.04
(0%)
Intel Corp.
INTC
$28.35
(+0.3%)
AT&T, Inc.
T
$20.37
(0%)
Unitedhealth Group Inc
UNH
$499.26
(+0.01%)
Cisco Systems, Inc.
CSCO
$48.10
(-1.17%)
PetroChina Co. Ltd. - ADR
PTR
$43.88
(0%)
Novartis AG - ADR
NVS
$87.68
(-3.24%)
Pfizer Inc.
PFE
$43.75
(-0.94%)
Taiwan Semiconductor Manufacturing - ADR
TSM
$93.19
(+0.5%)
No Result
View All Result
The Voice of All
  • Login
  • Home
  • Trend
  • News
    • United Stated
    • Asia
      • Japan
      • Pakistan
      • China
      • India
      • Singapore
    • Europe
      • France
      • Germany
      • Spain
      • United Kingdom
    • Canada
    • Middle East
    • Africa
  • Politics
  • Business
  • Economy
  • Culture
  • Health
  • Lifestyle
  • Sports
  • Tech
  • Videos
  • Travel
  • Blogs
Subscribe
  • Home
  • Trend
  • News
    • United Stated
    • Asia
      • Japan
      • Pakistan
      • China
      • India
      • Singapore
    • Europe
      • France
      • Germany
      • Spain
      • United Kingdom
    • Canada
    • Middle East
    • Africa
  • Politics
  • Business
  • Economy
  • Culture
  • Health
  • Lifestyle
  • Sports
  • Tech
  • Videos
  • Travel
  • Blogs
Subscribe
The Voice of All
No Result
View All Result
Home Business

BioNTech to return almost €2bn to shareholders after Covid vaccine success

March 30, 2022
in Business
0 0
A A
1
VIEWS
FacebookTwitterLinkedIn

BioNTech plans to return nearly €2bn to shareholders through share buybacks and a special dividend following the commercial success of its Covid-19 vaccine, the company said on Wednesday.

The German biotech, which launched the first Covid-19 vaccine in partnership with Pfizer, said it would also boost research and development spending by 50 per cent to €1.4bn to €1.5bn, as it seeks to develop a new range of drugs based on mRNA technology.

“To continue our industry leadership, we intend to build on our 2021 success and rapidly advance multiple programmes, including our mRNA-based immunotherapies, cell therapies, and bi-specific antibodies,” said Ugur Sahin, BioNTech’s co-founder and chief executive.

The biotech has multiple ongoing drug development programmes, including 16 cancer drug candidates in clinical trials.

BioNTech fortunes have soared following its December 2020 launch of the first vaccine using messenger ribonucleic acid, or mRNA technology. The Nasdaq-listed biotech now faces the challenge of bringing new drugs to market to diversify its revenue stream, with Covid vaccine sales expected to moderate as the pandemic eases.

Analysts said the biotech and its Covid vaccine rival Moderna face a delicate balancing act between investing the proceeds from vaccine sales in R&D and business development to expand their operations while also rewarding investors who backed both companies’ rapid rise from start-ups to global businesses.

BioNTech on Wednesday said it planned to repurchase $1.5bn of its shares over the next two years. It also proposed paying a special cash dividend of €2 a share, worth about €486mn. Meanwhile, Moderna last month announced a $3bn buyback but did not propose a special dividend.

Brad Loncar, a biotech investor, said BioNTech and Moderna faced challenges because they attracted a “fast-money” shareholder base during the pandemic that expects them to produce many new products in the short term.

“Drug development doesn’t work that way and these are going to be much longer-term stories than many realise,” he said. “By adding a modest income component to their stocks, I think they can attract more long term-oriented investors who have the patience to see the non-Covid pipeline play out over the years it will take in reality.”

BioNTech said it would expand an ongoing clinical trial for a Covid-19 vaccine tailored to boost protection against the Omicron variant and would publish data in April. It is also working on next generation Covid vaccines, which are intended to offer broader protection against new variants. But human trials have not yet begun, said the company.

The announcement accompanied fourth-quarter results, which topped analysts’ earnings forecasts. BioNTech earned €12.18 a share in the fourth quarter, compared with analysts’ estimates of €8.19 a share.

For the full year the company reported €18.9bn in revenues, compared with €482.3mn a year earlier — a result that reflects the phenomenal success of the Covid-19 vaccine in 2021. Full-year net profit was €10.2bn, compared with €15.2mn in 2020.

The company said it had signed orders for delivery of 2.4bn Covid vaccines in 2022, which it expects to generate between €13bn and €17bn in revenues.

Shares in BioNTech were up almost 5 per cent in morning trade.

This article has been amended to correct the value of BioNTech’s share buybacks

Source: Financial Times

ADVERTISEMENT

Related Posts

Business

‘One long day in hell’: Ukrainian PoWs recall desperate fight for Mariupol

Business

Investors hold steady ahead of US inflation data

Business

Kenya Discloses Part of Secret Railway Contract With China

Business

Renault seeks to boost operating margins and reinstate dividends

Business

Debt, Ukraine and Hunter Biden: Republicans prepare for House majority

Business

Pension funds after the gilts crisis: the big asset allocation rethink

Business

India’s coming decade of outperformance 

Business

Taiwan’s bank problem for companies expanding abroad

Business

Hong Kong takes on Singapore for Asia’s crypto crown

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Trending

    Latest News

    Here’s how ranked-choice voting works.

    Here’s how ranked-choice voting works.

    Jovan Adepo and Thundercat on Jazz, Superheroes and Ego Death

    You’ve Planned the Holiday Menu. Now Where Will You Put All the Guests?

    The Return of the Jaguar

    The Voice of All

    The Voice of All is an online newspaper for cosmopolitans, global entrepreneurs, management staff, influencers, and other modern leaders and everyday people who care about wider aspects and broader opinions.

    Sections

    • Africa
    • Asia
    • Business
    • Canada
    • China
    • Culture
    • Economy
    • Europe
    • France
    • Germany
    • Health
    • India
    • Japan
    • Lifestyle
    • Middle East
    • Pakistan
    • Politics
    • Singapore
    • Spain
    • Sports
    • Tech
    • Travel
    • United Kingdom
    • United Stated
    • Videos

    THE MOST IMPORTANT FINANCE NEWS AND EVENTS OF THE DAY

    Subscribe to our mailing list to receives daily updates direct to your inbox!

    • About
    • Advertise
    • Privacy Policy
    • Terms
    • Contact

    © 2022 All Rights Reserved - The Voice of All

    No Result
    View All Result
    • Home
    • Trend
    • News
      • United Stated
      • Asia
        • Japan
        • Pakistan
        • China
        • India
        • Singapore
      • Europe
        • France
        • Germany
        • Spain
        • United Kingdom
      • Canada
      • Middle East
      • Africa
    • Politics
    • Business
    • Economy
    • Culture
    • Health
    • Lifestyle
    • Sports
    • Tech
    • Videos
    • Travel
    • Blogs

    © 2022 All Rights Reserved - The Voice of All

    Welcome Back!

    Login to your account below

    Forgotten Password?

    Retrieve your password

    Please enter your username or email address to reset your password.

    Log In
    This website uses cookies. By continuing to use this website, you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.